Table 8:
Nonserious Adverse Events During and After MRgFUS Capsulotomy
| Adverse event reported | n (%) | Details |
|---|---|---|
| Davidson et al, 202072 | ||
| Headache | 3 (50%) | Duration <24 h to 5 d and resolved without intervention |
| Pin-site swelling | 2 (33.3%) | |
| Pin-site erythema | 2 (33.3%) | |
| Kim et al, 201879 | ||
| Headache - short, periodic, mild during procedure at high-temperature sonications | 7 (63.6%) | Resolved spontaneously or after 1 dose of analgesic medication |
| Nausea, vomiting, dizziness during procedure | 5 (45.5%) | Resolved at end of procedure or after 1 dose of antiemetic medication |
| Increased anxiety | 3 (27.3%) | Resolved after 1 dose of benzodiazepine |
| Stomach upset | 2 (18.2%) | Resolved with 1 dose of H2 blocker medication |
| Transient warm sensation in brain during high sonications | 1 (9.1%) | None reported |
Abbreviations: H2, histamine type 2 receptor; MRgFUS, magnetic resonance-guided focused ultrasound.